Novo Nordisk A/S
NVOToday
-2.01%
5 Days
-0.52%
1 Month
-3.98%
6 Months
+28.83%
Year to Date
-4.74%
1 Year
-12.42%
Recent
Analysis
Novo Nordisk A/S Stock (NVO) Moved Down by 3.32% on Aug 26: Drivers Behind the Movement
• Novo Nordisk faced downside pressure due to margin compression and pricing dynamics. • Intense competition from rival therapies heightened sensitivity to market share trends. • The stock reported an annual revenue of $46.70B and net profit of $15.48B.
Novo Nordisk A/S Stock (NVO) Closed Up by 3.71% on Aug 25: A Full Analysis
• Wall Street raised Novo Nordisk price targets and long-term financial forecasts. • Strong GLP-1 therapy adoption and share buybacks bolster market confidence. • The company reports $46.70B in annual revenue and $15.48B in net profit.
Novo Nordisk A/S Stock (NVO) Closed Up by 3.11% on Aug 6: What Investors Need To Know
• Novo Nordisk raised full-year sales and operating profit guidance amid strong metabolic drug demand. • Clinical data shows efficacy for cardiovascular and kidney diseases, expanding the potential patient base. • Current technical indicators show a neutral MACD signal and oversold Williams %R conditions.
Amgen Inc Stock (AMGN) Closed Up by 3.03% on Aug 4: Key Drivers Unveiled
• Amgen reported second-quarter earnings exceeding consensus estimates for revenue and earnings per share. • Positive interim clinical data for a metabolic health candidate drove share price appreciation. • Annual revenue reached $36.75 billion with the company ranking tenth in net profit.
Novo Nordisk A/S Stock (NVO) Moved Down by 8.75% on Jul 31: Key Drivers Unveiled
• Novo Nordisk shares declined following disappointing quarterly guidance and increased competitive pressure. • Rising operational costs and supply chain constraints are negatively impacting the company's margins. • Legislative uncertainty regarding U.S. drug pricing contributes to concerns over future revenue growth.
Novo Nordisk A/S Stock (NVO) Closed Up by 3.02% on Jul 15: Drivers Behind the Movement
• Novo Nordisk shares rose on manufacturing expansion and obesity treatment clinical milestones. • Semaglutide therapeutic expansion into kidney disease and metabolic conditions attracted institutional capital. • Robust free cash flow and market dominance provide stability amid broader economic uncertainty.
Novo Nordisk A/S's Score
Media Coverage
Analyst Rating
Novo Nordisk A/S Technical Analysis
Technical Indicators
Summary
Moving Average
Financial Indicators
Earnings
Novo Nordisk A/S Profile
Ownership
| Shareholders | Proportion |
|---|---|
| Loomis, Sayles & Company, L.P. | 0.51% |
| Dodge & Cox | 0.49% |
| Putnam Investment Management, L.L.C. | 0.43% |
| Capital International Investors | 0.33% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 4.28% |
| Investment Advisor/Hedge Fund | 3.10% |
| Research Firm | 1.11% |
| Hedge Fund | 0.63% |
Related Instruments
Popular Instruments
